LYEL ▼ -5.3% - Lyell Immunopharma, Inc. $LYEL - Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer Lyell Immunopharma fell 5.3% today following news that the company completed a manufacturing transfer for its LYL273 candidate and updated its timeline for a Phase 1/2 trial in metastatic colorectal cancer. While the manufacturing milestone represents operational progress, the updated trial timeline may have disappointed investors expecting faster advancement of the program. 10-SEP-2026 04:05 PM ET